TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7963049
Drug: Unstructured medication
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unstructured medication education
Study: 30987917
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase beta 0.5 mg/kg 2-weekly
Study: 30987917
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase beta 1.0 mg/kg 4-weekly
Study: 27862727
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of type A botulinum toxin (BoNTA)
Study: 27862727
Drug: Intradermal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal saline solution injection (Control)
Study: 17692742
Drug: Candesartan and
Normalized name: candesartan and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan and spironolactone (combination group)
Study: 11526203
Drug: Malaria DNA
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaria DNA vaccine administered by needle i.m. or needleless jet injection
Study: 9817534
Drug: Long-term treatments
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatments for multiple sclerosis
Study: 7544030
Drug: Paclitaxel (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (up to 250 mg/m2) followed by Carboplatin (up to 400 mg/m2)
Study: 7544030
Drug: Carboplatin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (300 mg/m2) with Paclitaxel (200 mg/m2)
Study: 7544030
Drug: Paclitaxel (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (250 mg/m2) with Carboplatin (350 mg/m2)
Study: 7544030
Drug: Paclitaxel (above
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (above 200 mg/m2)
Study: 2652281
Drug: Six-month therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six-month therapy with a fixed combination of 120 mg rifampicin, 50 mg isoniazid, and 300 mg pyrazinamide (Rifater)
Study: 2652281
Drug: Present Swiss
Normalized name: Swiss Kriss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present Swiss standard therapy (Daily rifampicin, isoniazid, and ethambutol for 2 months followed by rifampicin and isoniazid for 7 months)
Study: 788758
Drug: Pindolol administered
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol administered once daily
Study: 788758
Drug: Propranolol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol administered once daily
Study: 788758
Drug: Beta-adrenoceptor blocking
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoceptor blocking drugs (general)
Study: 23168523
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg BID)
Study: 30863471
Drug: USG bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: USG bilateral subcostal TAP block with 0.3 ml/kg bupivacaine
Study: 30863471
Drug: USG bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: USG bilateral QL block with 0.3 ml/kg bupivacaine
Study: 21390582
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage of Astragalus granule (7.5 g)
Study: 21390582
Drug: Moderate dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dosage of Astragalus granule (4.5 g)
Study: 21390582
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage of Astragalus granule (2.25 g)
Study: 17261465
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg)
Study: 17443000
Drug: Interleukin-2-based immunotherapy
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2-based immunotherapy
Study: 3528979
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone
Study: 11440296
Drug: Postal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postal and telephone reminders during the first 2 months of pravastatin treatment
Study: 9754889
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg in D5W
Study: 8058228
Drug: Metronidazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (400 mg twice daily) for two 2-day courses, first at 24 weeks' gestation and second at 29 weeks if G vaginalis was present.
Study: 2702513
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of nasally applied budesonide twice daily
Study: 2702513
Drug: 250 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 micrograms of orally administered budesonide twice daily
Study: 769572
Drug: Pyrimethamine 75
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrimethamine 75 mg and sulfadoxine 1,500 mg
Study: 769572
Drug: Pyrimethamine 50
Normalized name: pyrimethamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine 50 mg and diformyldapsone 800 mg
Study: 10481867
Drug: Intron-A (interferon-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intron-A (interferon-alpha 2b) at standard doses (5 IU/m2/day)
Study: 10481867
Drug: Low-dose interferon-alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interferon-alpha-2b (reaferon and intron-A, 1-3 IU/m2/day) in combination with chemotherapy
Study: 18637534
Drug: Zinc therapy
Normalized name: PYRITHIONE ZINC 2 g in 100 g TOPICAL SOAP [Zinc Therapy]
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc therapy
Study: 23448393
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery by MDLAP
Study: 21314329
Drug: Curcumin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin administration
Study: 19824094
Drug: NaHCO3 infusion
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaHCO3 infusion
Study: 10783014
Drug: aP vaccine
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aP vaccine
Study: 10783014
Drug: TdaP‐IPV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: TdaP‐IPV vaccine
Study: 10783014
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of acellular pertussis vaccine
Study: 8854782
Drug: Arterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arterial infusion (AI) chemotherapy
Study: 1616115
Drug: Droperidol (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (0.075 mg/kg)
Study: 1616115
Drug: Metoclopramide (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (0.15 mg/kg)
Study: 1616115
Drug: NaCl (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (0.1 ml/kg)
Study: 29767728
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg andecaliximab every 2 weeks (Q2W)
Study: 29767728
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg andecaliximab weekly (QW)
Study: 29767728
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg andecaliximab Q2W and QW
Study: 29767728
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg andecaliximab and placebo
Study: 25252254
Drug: Oral-B 3D
Normalized name: Oral-B 3D White Luxe Pulsar Toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B 3D White
Study: 20164411
Drug: Daily reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily reinforcement of speed (DRS) after a single, daily 10-m walk
Study: 20164411
Drug: Daily reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily reinforcement of speed (DRS)
Study: 17379123
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine 0.5 mg/kg in 2 mL saline before surgery, followed by continuous IV infusion of ketamine at 6 micro/(kg/min)
Study: 17379123
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (10 mL/h) until bleeding control, with 0.8 mg/kg ketamine during bleeding control in 2 mL saline
Study: 15747897
Drug: Adjunctive subantimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive subantimicrobial dose doxycycline (SDD; 20 mg doxycycline twice daily)
Study: 11874994
Drug: PPI +
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI + 1 day of H2RA (ranitidine 300 mg)
Study: 11874994
Drug: PPI twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI twice daily alone
Study: 11874994
Drug: PPI twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI twice daily + H2RA after 1 week
Study: 28122105
Drug: Acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (600 mg orally, once daily) for 10 days
Study: 28122105
Drug: Acetylcysteine with
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcysteine with amoxicillin‐clavulanic acid, pseudoephedrine, and intranasal normal saline
Study: 17097398
Drug: Topical retapamulin
Normalized name: retapamulin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retapamulin ointment 1% (twice daily for 5 days)
Study: 17097398
Drug: Oral cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cephalexin (500 mg twice daily for 10 days)
Study: 14984435
Drug: TGZ 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGZ 600 mg daily
Study: 14984435
Drug: TGZ 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGZ 200 mg daily
Study: 9524792
Drug: Rifaximin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (100 mg every six hours for an average of four days)
Study: 9524792
Drug: Paromomycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin (125 mg every six hours for an average of four days)
Study: 8292061
Drug: Eryfer 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eryfer 100 (100 mg Fe++)
Study: 8292061
Drug: Eryfer (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eryfer (50 mg Fe++)
Study: 29371381
Drug: Inhaled diesel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled diesel exhaust (DE) combined with allergen exposure
Study: 29371381
Drug: Inhaled diesel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled diesel exhaust (DE) alone
Study: 24560541
Drug: Vaccine (Merck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (Merck Ad5 gag/pol/nef subtype B HIV‐1 preventive vaccine)
Study: 22563210
Drug: Ertapenem, 1
Normalized name: Ertapenem, 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem, 1 g once daily
Study: 22563210
Drug: Ceftriaxone, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone, 2 g once daily
Study: 12455806
Drug: Intravenous cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefazolin 1 gm every 8 hours for 3 days, then oral cephalexin 500 mg every 6 hours for 4 days
Study: 7085368
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prophylactic antibiotics)
Study: 12455806
Drug: Intravenous cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefazolin followed by oral cephalexin
Study: 10348767
Drug: Azithromycin 1
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1 g orally once on the first day, followed by 500 mg orally once daily for the next 6 days
Study: 9780257
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg orally twice daily for 7 days
Study: 7589012
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) 20 mg i.v. bolus
Study: 7589012
Drug: Insulin (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.15 IU kg-1)
Study: 2031508
Drug: 5-fluorouracil (5-FU),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (5-FU), 1,200 mg/m2 i.v. infusion over 2 h
Study: 2031508
Drug: Methotrexate (MTX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (MTX), 200 mg/m2 i.v. (push injection), followed 20 h later by 5-FU, 1,200 mg/m2 i.v. infusion over 2 h, plus calcium leucovorin (LV), 25 mg i.m. every 6 h for eight doses beginning 24 h after MTX administration
Study: 7146823
Drug: Subcutaneous calcium‐heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous calcium‐heparin (5000 IU every 12 h for at least 2 weeks)
Study: 7146823
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K (for 15 days) followed by subcutaneous calcium‐heparin (5000 IU every 12 h for at least 2 weeks)
Study: 7146823
Drug: Subcutaneous calcium‐heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous calcium‐heparin (5000 IU every 12 h for at least 2 weeks) started immediately
Study: 6375891
Drug: Hyposensitization treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyposensitization treatment with tyrosine-adsorbed Dermatophagoides pteronyssinus antigen
Study: 2682160
Drug: Hyposensitization treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyposensitization treatment
Study: 26508309
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (AA) 1000mg orally once daily plus prednisone 5mg orally twice daily
Study: 20353449
Drug: Interviewer-administered Child-OIDP
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered Child-OIDP
Study: 20353449
Drug: Self-administered Child-OIDP
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered Child-OIDP
Study: 11936482
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments pooled
Study: 10086434
Drug: High-dose methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methadone (80 to 100 mg)
Study: 10086434
Drug: Moderate-dose methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose methadone (40 to 50 mg)
Study: 8665532
Drug: Cycloserine treatment
Normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycloserine treatment (various dosages)
Study: 2694356
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment
Study: 7004474
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg orally nightly for 1 week
Study: 7004474
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg rectally nightly for 1 week
Study: 7004474
Drug: Indomethacin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (oral and rectal)
Study: 7004474
Drug: Indomethacin (oral)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (oral)
Study: 7004474
Drug: Indomethacin (rectal)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (rectal)
Study: 30444191
Drug: Combination Treatment
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Treatment (COM)
Study: 23273827
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving standard attention without specific treatment
Study: 22331954
Drug: Sunitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib plus docetaxel (sunitinib 37.5 mg/d, days 2 to 15 every 3 weeks; docetaxel 75 mg/m2, day 1 every 3 weeks)
Study: 22331954
Drug: Docetaxel alone
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel alone (100 mg/m2 every 3 weeks)
Study: 16973657
Drug: Ciclosporin, Tacrolimus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin, Tacrolimus, or p55TNFr-Ig (anti-TNF agent)
Study: 11223695
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium diet (< 600 mg/day)
Study: 9393299
Drug: TUR plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TUR plus BCG therapy
Study: 7896386
Drug: Folifer and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folifer and calcium tablets supplied from second trimester till delivery along with regular medical supervision and nutrition education.
Study: 3630961
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement of 100 g/d of mackerel
Study: 14672296
Drug: Meat supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat supplement
Study: 28340086
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (10 sessions with licensed massage therapists)
Study: 17083652
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg of sublingual misoprostol with vaginal placebo (n = 70)
Study: 17083652
Drug: 25 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg of vaginal misoprostol with sublingual placebo (n = 70)
Study: 15684166
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg of sublingual misoprostol
Study: 15313947
Drug: Xuezhikang 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang 1200 mg/d
Study: 8935811
Drug: Amisulpride (630-910
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (630-910 mg/day)
Study: 8935811
Drug: Amisulpride (1100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (1100 mg/day)
Study: 1589668
Drug: Amoxicillin 750
Normalized name: amoxicillin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 750 mg b.i.d. for 7 days
Study: 12203058
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture, group H (3.45 +/- 0.07 g/kg per day)
Study: 12203058
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture, group M (2.59 +/- 0.07 g/kg per day)
Study: 12203058
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture, group L (1.72 +/- 0.06 g/kg per day)
Study: 8910647
Drug: Ultrasensitive enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasensitive enzyme immunoassay for simultaneous detection of p24 antigen and antibody IgGs to p17 and reverse transcriptase of HIV-1
Study: 8910647
Drug: Conventional methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional methods for HIV-1 antibody detection
Study: 8478300
Drug: Dirithromycin 500
Normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dirithromycin 500 mg once daily (od)
Study: 8478300
Drug: Miocamycin 600
Normalized name: miocamycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miocamycin 600 mg twice daily (bd)
Study: 3515921
Drug: Flurbiprofen 100
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 100 mg BID (twice daily)
Study: 3515921
Drug: Flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50 mg QID (four times daily)
Study: 3515921
Drug: Flurbiprofen treatment
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen treatment (both regimens)
Study: 29553418
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg preservative-free morphine
Study: 29553418
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg fentanyl
Study: 29058837
Drug: Oxycodone (Oxynorm®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (Oxynorm® instant)
Study: 24159772
Drug: Prostatotropic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostatotropic drug Vitaprost along with comprehensive treatment including preoperative trophic and flebotonic therapy, laparoscopic surgical clipping of the internal spermatic vein, and post-operative rehabilitation.
Study: 24159772
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment including preoperative trophic and flebotonic therapy, laparoscopic surgical clipping of the internal spermatic vein, and post-operative rehabilitation without Vitaprost.
Study: 21495322
Drug: Chlorhexidine digluconat
Normalized name: Chlorhexidine digluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine digluconat 0.2% for mouthrinsing twice a day
Study: 21495322
Drug: NaF 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF 0.05% for mouthrinsing twice a day
Study: 9686089
Drug: Sufentanil group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil group (0.2 mg.kg‐1 sufentanil added to 0.5% bupivacaine 1 mg.kg‐1 and 1% lidocaine 2 mg.kg‐1)
Study: 9686089
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.5% bupivacaine 1 mg.kg‐1 and 1% lidocaine 2 mg.kg‐1)
Study: 22634908
Drug: Group MC
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group MC - morphine 0.1 mg/ml and clonidine 5 μg/ml continuously infused at 5 ml/h
Study: 22634908
Drug: Group BM
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group BM - bupivacaine 0.125% and morphine 0.1 mg/ml